

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Marshall D. Crew, et al.

APPLICATION NO.: 10/066,091

Examiner: Unknown

FILING DATE: February 1, 2002

:Group Art Unit: 1614

TITLE: Pharmaceutical Compositions of Cholesteryl Ester:  
Transfer Protein Inhibitors

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

AMENDMENT AND RESPONSE TO NON-FINAL OFFICE ACTION

This is in response to the non-Final Office Action dated December 29, 2005 in the above-identified application, the term for response having been extended three (3) months to June 29, 2006 by including the appropriate fee and petition herewith.

A claims summary is appended hereto, starting on its own separate sheet.

REMARKS

As a preliminary matter, attention is directed to the Petition For Extension of Time of three months included herewith, which includes authorization to charge fees to the deposit account of Pfizer Inc.

In the discussion that follows, references made to text supporting the amendments made herein are to published US application 2003/0186952 A1. Reference to supporting text is generally made by referring to particular numbered paragraph, i.e., the bracketed paragraph number set forth in the US published application.

Claims 1, 6 and 13 have been amended to specify a particular class of compounds, i.e., those of Formula IV, as detailed in Applicants' specification. Support is in the specification at paragraphs [0147] to [0169].

The aforementioned claims have also been amended to specify a particular group of concentration-enhancing polymers, namely those specified in paragraph [1077].

New claims 43 and 44 have been added. Claim 43 is multiply dependent from independent claims 1, 6, and 13, and specifies the particular group of cholesteryl ester